BrainsWay Ltd. (NASDAQ:BWAY - Free Report) - Investment analysts at Northland Capmk lowered their Q1 2025 earnings estimates for shares of BrainsWay in a note issued to investors on Tuesday, March 11th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings per share of $0.01 for the quarter, down from their previous estimate of $0.02. The consensus estimate for BrainsWay's current full-year earnings is $0.08 per share. Northland Capmk also issued estimates for BrainsWay's Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.08 EPS and FY2026 earnings at $0.15 EPS.
Separately, HC Wainwright reiterated a "buy" rating and issued a $16.00 price objective on shares of BrainsWay in a research note on Wednesday, March 12th.
Read Our Latest Research Report on BWAY
BrainsWay Stock Down 0.3 %
Shares of NASDAQ BWAY traded down $0.03 during midday trading on Friday, hitting $10.18. The company had a trading volume of 44,790 shares, compared to its average volume of 75,628. BrainsWay has a twelve month low of $4.61 and a twelve month high of $11.79. The business has a 50-day simple moving average of $10.27 and a two-hundred day simple moving average of $9.64. The firm has a market capitalization of $191.66 million, a price-to-earnings ratio of 101.81 and a beta of 1.29.
Institutional Trading of BrainsWay
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC acquired a new position in BrainsWay during the 4th quarter worth approximately $44,000. JPMorgan Chase & Co. grew its stake in BrainsWay by 316.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company's stock worth $136,000 after buying an additional 11,221 shares during the last quarter. Sei Investments Co. bought a new position in BrainsWay during the 4th quarter worth $149,000. Cubist Systematic Strategies LLC grew its stake in shares of BrainsWay by 14.6% in the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company's stock worth $181,000 after purchasing an additional 2,446 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in shares of BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock worth $207,000 after purchasing an additional 2,144 shares in the last quarter. Hedge funds and other institutional investors own 30.11% of the company's stock.
BrainsWay Company Profile
(
Get Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Featured Articles
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
